
News|Videos|August 1, 2024
Emerging Treatments in Mild/Moderate Multiple Sclerosis
Key opinion leaders examine the available data on Bruton tyrosine kinase (BTK) inhibitors to assess whether the evidence supports their efficacy as a treatment option for multiple sclerosis (MS).
Advertisement
Episodes in this series

BTK inhibitors: Do the current data suggest this strategy for mild MS?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook
2
CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS
3
FDA Approves Inebilizumab for Myasthenia Gravis, Phase 3 PREVAiLS Study Launched, Tolebrutinib Fails Phase 3 PERSEUS Study
4
What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers
5
















